Core Viewpoint - Health Catalyst (HCAT) reported quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share, but showing an improvement from $0.04 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was -14.26%, with the company previously expected to post earnings of $0.05 per share but actually reporting $0.06, resulting in a +20% surprise [2] - Health Catalyst generated revenues of $74.68 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 1.45%, although this is a decline from $79.61 million in the same quarter last year [3] Stock Performance - Health Catalyst shares have declined approximately 22.2% since the beginning of the year, contrasting with a 1% decline in the S&P 500 [4] - The company's current Zacks Rank is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $73.37 million, and for the current fiscal year, it is $0.30 on revenues of $300.34 million [8] - The Medical Info Systems industry, to which Health Catalyst belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [9]

Core Insights - Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.07 per share a year ago [1][2] - The company achieved a revenue of $76.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.66%, and slightly down from $76.35 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +20.00%, following a previous surprise of +33.33% when earnings were $0.04 per share against an expectation of $0.03 [2] - Over the last four quarters, Health Catalyst has exceeded consensus EPS estimates two times and revenue estimates three times [2][3] Stock Performance - Health Catalyst shares have declined approximately 60% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, and for the current fiscal year, it is $0.19 on revenues of $309.8 million [8] - The Medical Info Systems industry, to which Health Catalyst belongs, is ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

Core Insights - Health Catalyst (HCAT) reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, but down from $0.12 per share a year ago, indicating an earnings surprise of +33.33% [1] - The company generated revenues of $80.72 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.24% and up from $75.9 million year-over-year [2] - Health Catalyst shares have declined approximately 46% year-to-date, contrasting with the S&P 500's gain of 7.9% [3] Earnings Outlook - The future performance of Health Catalyst's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $85.38 million, and for the current fiscal year, it is $0.24 on revenues of $334.82 million [7] Industry Context - The Medical Info Systems industry, to which Health Catalyst belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]